Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-06-19

AUTHORS

H. Ideguchi, S. Ohno, H. Hattori, Y. Ishigatsubo

ABSTRACT

The real cumulative persistence probabilities with bisphosphonates after 5 years was 51.7%. Prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.IntroductionMany patients discontinue daily bisphosphonate therapy prematurely due to the stringent dosing procedures and adverse events. Consequently, some patients are receiving two or more sequential bisphosphonates in daily practice. Our objective was to study factors associated with the real cumulative persistence with bisphosphonate therapy including treatment courses with multiple sequential drugs in the real world setting.MethodsWe retrospectively analyzed 1,307 patients (male 197, female 1110) newly prescribed with bisphosphonates between January 1, 2000, and June 30, 2005.ResultsThe real cumulative persistence probabilities with bisphosphonates after 1, 3, and 5 years were 74.8%, 60.6%, and 51.7%, respectively. Switching of bisphosphonates was observed 168 times in 146 patients. Adverse events occurred 126 times in 124 patients including 86 events with gastrointestinal complaints. Univariate analysis showed that prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.ConclusionsSwitching of bisphosphonates was not uncommon. Despite switching bisphosphonates to improve persistence, the real cumulative persistence with bisphosphonate was suboptimal, especially among patients of certain physician specialties and male sex. More... »

PAGES

1421-1427

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-007-0406-0

DOI

http://dx.doi.org/10.1007/s00198-007-0406-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1013678762

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17577595


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Self Administration", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ideguchi", 
        "givenName": "H.", 
        "id": "sg:person.01324761473.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324761473.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohno", 
        "givenName": "S.", 
        "id": "sg:person.013722512012.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722512012.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "H.", 
        "id": "sg:person.01305201036.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201036.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Y.", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-006-0179-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038026469", 
          "https://doi.org/10.1007/s00198-006-0179-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0073-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020337646", 
          "https://doi.org/10.1007/s00198-006-0073-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1431-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032558418", 
          "https://doi.org/10.1007/s00198-003-1431-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-004-1818-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019683703", 
          "https://doi.org/10.1007/s00198-004-1818-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-002-1370-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021711183", 
          "https://doi.org/10.1007/s00198-002-1370-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001980200135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033038209", 
          "https://doi.org/10.1007/s001980200135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00534-005-1046-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009417908", 
          "https://doi.org/10.1007/s00534-005-1046-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-006-0136-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031571579", 
          "https://doi.org/10.1007/s00198-006-0136-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-06-19", 
    "datePublishedReg": "2007-06-19", 
    "description": "The real cumulative persistence probabilities with bisphosphonates after 5\u00a0years was 51.7%. Prescriptions by specialists other than gynecologists and rheumatologists (p\u2009<\u20090.001), male sex (p\u2009<\u20090.001), older age (\u226565\u00a0years) (p\u2009=\u20090.001), and cyclical etidronate (p\u2009<\u20090.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.IntroductionMany patients discontinue daily bisphosphonate therapy prematurely due to the stringent dosing procedures and adverse events. Consequently, some patients are receiving two or more sequential bisphosphonates in daily practice. Our objective was to study factors associated with the real cumulative persistence with bisphosphonate therapy including treatment courses with multiple sequential drugs in the real world setting.MethodsWe retrospectively analyzed 1,307 patients (male 197, female 1110) newly prescribed with bisphosphonates between January 1, 2000, and June 30, 2005.ResultsThe real cumulative persistence probabilities with bisphosphonates after 1, 3, and 5\u00a0years were 74.8%, 60.6%, and 51.7%, respectively. Switching of bisphosphonates was observed 168 times in 146 patients. Adverse events occurred 126 times in 124 patients including 86 events with gastrointestinal complaints. Univariate analysis showed that prescriptions by specialists other than gynecologists and rheumatologists (p\u2009<\u20090.001), male sex (p\u2009<\u20090.001), older age (\u226565\u00a0years) (p\u2009=\u20090.001), and cyclical etidronate (p\u2009<\u20090.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.ConclusionsSwitching of bisphosphonates was not uncommon. Despite switching bisphosphonates to improve persistence, the real cumulative persistence with bisphosphonate was suboptimal, especially among patients of certain physician specialties and male sex.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-007-0406-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "bisphosphonate therapy", 
      "male sex", 
      "cyclical etidronate", 
      "adverse events", 
      "treatment course", 
      "cumulative persistence", 
      "older age", 
      "success rate", 
      "IntroductionMany patients", 
      "gastrointestinal complaints", 
      "univariate analysis", 
      "physician specialty", 
      "bisphosphonates", 
      "patients", 
      "real-world setting", 
      "sequential drugs", 
      "therapy", 
      "daily practice", 
      "rheumatologists", 
      "etidronate", 
      "gynecologists", 
      "sex", 
      "age", 
      "prescription", 
      "low persistence", 
      "world settings", 
      "years", 
      "MethodsWe", 
      "complaints", 
      "persistence", 
      "course", 
      "specialists", 
      "drugs", 
      "events", 
      "rate", 
      "specialties", 
      "setting", 
      "factors", 
      "time", 
      "procedure", 
      "objective", 
      "practice", 
      "analysis", 
      "probability", 
      "world", 
      "real world", 
      "persistence probability"
    ], 
    "name": "Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world", 
    "pagination": "1421-1427", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1013678762"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-007-0406-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17577595"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-007-0406-0", 
      "https://app.dimensions.ai/details/publication/pub.1013678762"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_440.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-007-0406-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0406-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0406-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0406-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-007-0406-0'


 

This table displays all metadata directly associated to this object as RDF triples.

213 TRIPLES      22 PREDICATES      93 URIs      77 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-007-0406-0 schema:about N00d0aed578484031aab3089d75376c9b
2 N0485b92228f144f8bdec6f9921f9157d
3 N1591a77a15c342b588b15d0982c42552
4 N18ba3921cce14301a70f5669451cb18b
5 N470cd6a13d7a4aa3aeb70e3bf9c76fea
6 N47b361a345f0449ea7cff24c45a1f945
7 N4f9a20b0b7a54b0b8cb58bee53d7d983
8 Na432ead6b5214a0f878c66eb282b35f3
9 Nd2fb5ee8b12c4cdf86c7a34f0b94ab33
10 Ndf0d8141623544a0a61adce8b457ab83
11 Neeb07c82dc804a74a8f6d895f2deda2e
12 Nfc32801e20134049b398e7df7fa202c8
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author Ncdc07e7d7d4b4ec9b5ca1bda7b14af4b
16 schema:citation sg:pub.10.1007/s00198-002-1370-3
17 sg:pub.10.1007/s00198-003-1431-2
18 sg:pub.10.1007/s00198-004-1818-8
19 sg:pub.10.1007/s00198-006-0073-6
20 sg:pub.10.1007/s00198-006-0136-8
21 sg:pub.10.1007/s00198-006-0179-x
22 sg:pub.10.1007/s001980200135
23 sg:pub.10.1007/s00534-005-1046-4
24 schema:datePublished 2007-06-19
25 schema:datePublishedReg 2007-06-19
26 schema:description The real cumulative persistence probabilities with bisphosphonates after 5 years was 51.7%. Prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.IntroductionMany patients discontinue daily bisphosphonate therapy prematurely due to the stringent dosing procedures and adverse events. Consequently, some patients are receiving two or more sequential bisphosphonates in daily practice. Our objective was to study factors associated with the real cumulative persistence with bisphosphonate therapy including treatment courses with multiple sequential drugs in the real world setting.MethodsWe retrospectively analyzed 1,307 patients (male 197, female 1110) newly prescribed with bisphosphonates between January 1, 2000, and June 30, 2005.ResultsThe real cumulative persistence probabilities with bisphosphonates after 1, 3, and 5 years were 74.8%, 60.6%, and 51.7%, respectively. Switching of bisphosphonates was observed 168 times in 146 patients. Adverse events occurred 126 times in 124 patients including 86 events with gastrointestinal complaints. Univariate analysis showed that prescriptions by specialists other than gynecologists and rheumatologists (p < 0.001), male sex (p < 0.001), older age (≥65 years) (p = 0.001), and cyclical etidronate (p < 0.001) were significantly associated with low persistence. Success rates of switching bisphosphonate were 75.6%.ConclusionsSwitching of bisphosphonates was not uncommon. Despite switching bisphosphonates to improve persistence, the real cumulative persistence with bisphosphonate was suboptimal, especially among patients of certain physician specialties and male sex.
27 schema:genre article
28 schema:inLanguage en
29 schema:isAccessibleForFree false
30 schema:isPartOf N6968d2a9de1249f085dfc810f837241f
31 Na6577cb4a3be485d944c821ec6eb590a
32 sg:journal.1100834
33 schema:keywords IntroductionMany patients
34 MethodsWe
35 adverse events
36 age
37 analysis
38 bisphosphonate therapy
39 bisphosphonates
40 complaints
41 course
42 cumulative persistence
43 cyclical etidronate
44 daily practice
45 drugs
46 etidronate
47 events
48 factors
49 gastrointestinal complaints
50 gynecologists
51 low persistence
52 male sex
53 objective
54 older age
55 patients
56 persistence
57 persistence probability
58 physician specialty
59 practice
60 prescription
61 probability
62 procedure
63 rate
64 real world
65 real-world setting
66 rheumatologists
67 sequential drugs
68 setting
69 sex
70 specialists
71 specialties
72 success rate
73 therapy
74 time
75 treatment course
76 univariate analysis
77 world
78 world settings
79 years
80 schema:name Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world
81 schema:pagination 1421-1427
82 schema:productId N30f7e03d2ec6407091a8e3eb08065b8a
83 N3d397ac738b84867a32827ddabba95a1
84 N78569895b1f64ac99792907d565757b5
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013678762
86 https://doi.org/10.1007/s00198-007-0406-0
87 schema:sdDatePublished 2022-05-20T07:24
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Nc3498addc6284512a4dc956d6a5da89f
90 schema:url https://doi.org/10.1007/s00198-007-0406-0
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N00d0aed578484031aab3089d75376c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N0485b92228f144f8bdec6f9921f9157d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Osteoporosis
99 rdf:type schema:DefinedTerm
100 N1591a77a15c342b588b15d0982c42552 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Middle Aged
102 rdf:type schema:DefinedTerm
103 N181b18e35c99425a893c2f96d1db2107 rdf:first sg:person.013722512012.55
104 rdf:rest N3d585df92ea14c76a46c63deeba39847
105 N18ba3921cce14301a70f5669451cb18b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Diphosphonates
107 rdf:type schema:DefinedTerm
108 N30f7e03d2ec6407091a8e3eb08065b8a schema:name dimensions_id
109 schema:value pub.1013678762
110 rdf:type schema:PropertyValue
111 N3d397ac738b84867a32827ddabba95a1 schema:name doi
112 schema:value 10.1007/s00198-007-0406-0
113 rdf:type schema:PropertyValue
114 N3d585df92ea14c76a46c63deeba39847 rdf:first sg:person.01305201036.31
115 rdf:rest N8a63aebcbd45464599e011c4e9286db1
116 N470cd6a13d7a4aa3aeb70e3bf9c76fea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Self Administration
118 rdf:type schema:DefinedTerm
119 N47b361a345f0449ea7cff24c45a1f945 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Male
121 rdf:type schema:DefinedTerm
122 N4f9a20b0b7a54b0b8cb58bee53d7d983 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Bone Density Conservation Agents
124 rdf:type schema:DefinedTerm
125 N6968d2a9de1249f085dfc810f837241f schema:issueNumber 10
126 rdf:type schema:PublicationIssue
127 N78569895b1f64ac99792907d565757b5 schema:name pubmed_id
128 schema:value 17577595
129 rdf:type schema:PropertyValue
130 N8a63aebcbd45464599e011c4e9286db1 rdf:first sg:person.01125133646.44
131 rdf:rest rdf:nil
132 Na432ead6b5214a0f878c66eb282b35f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Drug Administration Schedule
134 rdf:type schema:DefinedTerm
135 Na6577cb4a3be485d944c821ec6eb590a schema:volumeNumber 18
136 rdf:type schema:PublicationVolume
137 Nc3498addc6284512a4dc956d6a5da89f schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 Ncdc07e7d7d4b4ec9b5ca1bda7b14af4b rdf:first sg:person.01324761473.79
140 rdf:rest N181b18e35c99425a893c2f96d1db2107
141 Nd2fb5ee8b12c4cdf86c7a34f0b94ab33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Retrospective Studies
143 rdf:type schema:DefinedTerm
144 Ndf0d8141623544a0a61adce8b457ab83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Aged
146 rdf:type schema:DefinedTerm
147 Neeb07c82dc804a74a8f6d895f2deda2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Time Factors
149 rdf:type schema:DefinedTerm
150 Nfc32801e20134049b398e7df7fa202c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:journal.1100834 schema:issn 0937-941X
160 1433-2965
161 schema:name Osteoporosis International
162 schema:publisher Springer Nature
163 rdf:type schema:Periodical
164 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
165 schema:familyName Ishigatsubo
166 schema:givenName Y.
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
168 rdf:type schema:Person
169 sg:person.01305201036.31 schema:affiliation grid-institutes:grid.413045.7
170 schema:familyName Hattori
171 schema:givenName H.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01305201036.31
173 rdf:type schema:Person
174 sg:person.01324761473.79 schema:affiliation grid-institutes:grid.413045.7
175 schema:familyName Ideguchi
176 schema:givenName H.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324761473.79
178 rdf:type schema:Person
179 sg:person.013722512012.55 schema:affiliation grid-institutes:grid.413045.7
180 schema:familyName Ohno
181 schema:givenName S.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722512012.55
183 rdf:type schema:Person
184 sg:pub.10.1007/s00198-002-1370-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021711183
185 https://doi.org/10.1007/s00198-002-1370-3
186 rdf:type schema:CreativeWork
187 sg:pub.10.1007/s00198-003-1431-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032558418
188 https://doi.org/10.1007/s00198-003-1431-2
189 rdf:type schema:CreativeWork
190 sg:pub.10.1007/s00198-004-1818-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019683703
191 https://doi.org/10.1007/s00198-004-1818-8
192 rdf:type schema:CreativeWork
193 sg:pub.10.1007/s00198-006-0073-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337646
194 https://doi.org/10.1007/s00198-006-0073-6
195 rdf:type schema:CreativeWork
196 sg:pub.10.1007/s00198-006-0136-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031571579
197 https://doi.org/10.1007/s00198-006-0136-8
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00198-006-0179-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038026469
200 https://doi.org/10.1007/s00198-006-0179-x
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s001980200135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033038209
203 https://doi.org/10.1007/s001980200135
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s00534-005-1046-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009417908
206 https://doi.org/10.1007/s00534-005-1046-4
207 rdf:type schema:CreativeWork
208 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
209 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
210 rdf:type schema:Organization
211 grid-institutes:grid.413045.7 schema:alternateName Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan
212 schema:name Chronic Intractable Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan
213 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...